Effects of Glucagon-Like Peptide-1 Analogs on Sexuality

NCT04687514 on ClinicalTrials.gov · last registry update 2022-09-07

A small phase 2 — 26 participants, against a typical 110. Completed 5 September 2022.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: University Hospital, Basel, Switzerland
Sponsor type: Other
Enrollment: 26
Started: 2021-05-05
Primary completion: 2022-09-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in sexual functioning, assessed with the German version of the Massachusetts General Hospital - Sexual Functioning Questionnaire (MGH-SFQ).

Conditions studied

Sexual Functioning

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.